Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 207 Show results per page	View Search Criteria \| Help With Results


1.		A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Closed				18 and over				Pharmaceutical / Industry				ML18491 NCT00118755


2.		A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Closed				18 and over				Pharmaceutical / Industry				ML18527 NCT00121836


3.		XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Closed				18 and over				Pharmaceutical / Industry				ML18530 NCT00127933

Last Modified: 11/7/2007 First Published: 11/1/2002


4.		Phase II/III Randomized Study of Capecitabine Versus Vinorelbine in Women With Metastatic Breast Cancer Previously Treated With Taxanes With or Without Anthracyclines

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Other				EORTC-10001 EORTC-16001O, IDBBC-EORTC-10001, NCT00049660


5.		Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 and over				Other				NBCG10 REK 378-04-03133, NMA 03-07568, NCT00201435


6.		The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 and over				Other				AG0501CR NCT00294359

Last Modified: 5/1/1998 First Published: 2/1/1998


7.		Phase III Open Label Randomized Study Comparing Capecitabine and Fluorouracil in Combination With Leucovorin Calcium as First Line Chemotherapy in Patients With Advanced and/or Metastatic Colorectal Carcinoma (Summary Last Modified 05/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				ROCHE-SO14695 NCI-V97-1320

Last Modified: 7/12/2005 First Published: 2/1/2001


8.		Phase III Randomized Study of Adjuvant Capecitabine Versus Fluorouracil and Low-Dose Leucovorin Calcium in Chemotherapy Naive Patients With Previously Resected Stage III Colon Cancer (Summary Last Modified 12/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 75				Pharmaceutical / Industry				ROCHE-M66001 NCT00009737

Last Modified: 9/6/2005 First Published: 3/1/2001


9.		Phase III Randomized Study of Bevacizumab With Capecitabine Versus Capecitabine Alone in Women With Previously Treated Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				GENENTECH-AVF2119g GUMC-00299, MSKCC-01008, UAB-0028, UAB-F001009003, NCT00012285

Last Modified: 7/18/2008 First Published: 9/1/2001


10.		Phase III Randomized Study of Adjuvant Chemotherapy Comprising Standard Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) or Doxorubicin and Cyclophosphamide (AC) Versus Oral Capecitabine in Elderly Women With Operable Adenocarcinoma of the Breast

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				65 and over				NCI				CALGB-49907 ECOG-CALGB-49907, CAN-NCIC-MAC1, SWOG-CALGB-49907, NCT00024102, MAC1

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute